FMP

FMP

Enter

ENTA - Enanta Pharmace...

photo-url-https://images.financialmodelingprep.com/symbol/ENTA.png

Enanta Pharmaceuticals, Inc.

ENTA

NASDAQ

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

6.65 USD

-0.18 (-2.71%)

Historical Prices

From:

To:

6.646.76.86.977.0309:30 AM09:45 AM10:01 AM10:19 AM10:33 AM10:56 AM11:11 AM11:32 AM11:55 AM12:20 PM12:39 PM01:03 PM01:24 PM01:39 PM02:08 PM02:25 PM02:40 PM03:18 PM03:38 PM03:50 PM

About

ceo

Dr. Jay R. Luly Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

CIK

0001177648

ISIN

US29251M1062

CUSIP

29251M106

Address

500 Arsenal Street

Phone

617 607 0800

Country

US

Employee

131

IPO Date

Mar 21, 2013

Financial Statement

-40M-30M-20M-10M010M20M2024 Q12024 Q22024 Q32024 Q42025 Q1RevenueNet Income

Earnings

-2.5-2-1.5-1-0.502023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q4EPS Consensus

ENTA Financial Summary

CIK

0001177648

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

29251M106

ISIN

US29251M1062

Country

US

Price

6.65

Beta

0.48

Volume Avg.

539.27k

Market Cap

141.86M

Shares

-

52-Week

4.71-17.8

DCF

-7.91

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.34

P/B

-

Website

https://www.enanta.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest ENTA News

Zacks Investment Research

Aug 5, 2024

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue ...

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.86 per share a year ago.

Zacks Investment Research

Jul 15, 2024

Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside ...

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Business Wire

May 29, 2024

Enanta Pharmaceuticals to Participate at the Jefferies Globa...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY. A live webcast of the even.

Seeking Alpha

May 6, 2024

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Tr...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q2 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Scott Rottinghaus - Chief Medical Officer Tara Kieffer - Chief Product Strategy Officer Conference Call Participants Eric Joseph - JPMorgan Roy Buchanan - Citizens JMP Nik Gasic - Leerink Partners Jay Olson - Oppenheimer Operator Good afternoon and welcom...

Zacks Investment Research

May 6, 2024

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue ...

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.47 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.79 per share a year ago.

Seeking Alpha

Feb 7, 2024

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Tr...

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Zacks Investment Research

Feb 7, 2024

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue ...

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago.

Business Wire

Jan 31, 2024

Enanta Pharmaceuticals to Host Conference Call on February 7...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2023 after the U.S. market closes on February 7, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company's bu.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep